

# **Resistance to Targeted Anti-Cancer Therapeutics**

Volume 6

## **Series Editor**

Benjamin Bonavida

Department of Microbiology, Immunology, and Molecular Genetics,  
David Geffen School of Medicine, Jonsson Comprehensive Cancer Center,  
University of California of Los Angeles, Los Angeles, CA, USA

For several decades, treatment of cancer consisted of chemotherapeutic drugs, radiation, and hormonal therapies. Those were not tumor-specific and exhibited severe toxicities in many cases. But during the last several years, targeted cancer therapies have been developed. Targeted cancer therapies are drugs or other agents (e.g. antibodies) that block the growth and spread of cancer by interfering with specific gene products that regulate tumor cell growth and progression. Targeted cancer therapies are also sometimes called “molecularly targeted drugs.” We have witnessed in the last decade a significant explosion in the development of targeted cancer therapies developed against various specific cancers. These include drugs/antibodies that interfere with cell growth signaling or tumor blood vessel development, promote the cell death of cancer cells, stimulate the immune system to destroy specific cancer cells and to deliver toxic drugs to cancer cells. One of the major problems that arises following treatment with both conventional therapies and targeted cancer therapies is the development of resistance, preexisting in a subset of cancer cells or cancer stem cells and/or induced by the treatments. Tumor cell resistance to therapies remains a major problem and several strategies are being considered to reverse the resistance to various manipulations.

*Resistance to Targeted Anti-Cancer Therapeutics* will focus on the basic and translational research behind the molecular mechanisms of resistance found in many kinds of anti-cancer therapeutics.

More information about this series at <http://www.springer.com/series/11727>

Rama Shanker Verma  
Editor

# Resistance to Immunotoxins in Cancer Therapy

 Springer

*Editors*

Rama Shanker Verma  
Department of Biotechnology  
Indian Institute of Technology Madras  
Chennai  
India

Benjamin Bonavida  
Department of Microbiology  
Immunology, and Molecular Genetics  
David Geffen School of Medicine  
Jonsson Comprehensive Cancer Center  
University of California of Los Angeles  
Los Angeles, CA  
USA

ISSN 2196-5501

ISSN 2196-551X (electronic)

Resistance to Targeted Anti-Cancer Therapeutics

ISBN 978-3-319-17274-3

ISBN 978-3-319-17275-0 (eBook)

DOI 10.1007/978-3-319-17275-0

Library of Congress Control Number: 2015938912

Springer Cham Heidelberg New York Dordrecht London

© Springer International Publishing Switzerland 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

# Preface

Cancer includes a large class of diseases of abnormal cell growth and is the most life-threatening disease mankind has ever seen; it accounted for an astonishing 14.6% of all human deaths globally, according to the world cancer report in 2014. In the United States, 18,860 projected new cases and 10,460 deaths were reported in 2014 for acute myeloid leukemia—the most common form of leukemia. Although most of the global research is focused on developing therapeutics for cancers and cancer-related diseases, the successful treatment of cancer has been limited—due primarily to the emergence of resistance that leads to recurrence of a more aggressive form of the disease. As a result, there is an urgent need to reconsider current strategies of treatment and investigate the mechanisms of resistance.

This volume focuses on mechanisms of resistance and strategies to improve targeted therapy using immunotoxins and related therapies. The development of recombinant immunotoxins, using toxins as killing moieties conjugated with antibodies or ligands against cancer cell surface proteins, met the criteria of improving specificity and the cytotoxicity. Immunotoxin therapy, due to its specificity, is one of the major strategies used in targeted therapy that has shown promise in clinical trials. The toxins used are usually derived from bacterial or plant toxins, which are highly immunogenic. To reduce immunogenicity, genetically engineered versions were made by either silencing immunogenic epitopes or developing humanized versions of immunotoxins. However, the emergence of resistance and failure of the immunotoxins in many clinical trials have raised concerns about their utility, although immunotoxin is still the most promising approach used so far. The targeted therapeutic approach has been an attractive alternative in contrast to conventional treatment modalities. The development of monoclonal antibodies to specific surface targets on cancer cells led to the exponential growth of targeted therapy for better efficacy; this is evident from the fact that several monoclonal antibody-based therapies have been approved by the FDA. (These antibodies were later modified into single chain and recombinant versions.) Further, to minimize immunogenicity, humanized monoclonal antibodies were developed and, to improve activity, antibodies were conjugated with drugs or protein toxins. However, the problems of immunogenicity, specificity, and toxicity have yet to be completely eliminated.

Chapter 1 describes the history, construction, and types of immunotoxins developed to date. Chapter 2 presents a comprehensive view of resistance to cancers, different mechanisms involved in immunotoxin resistance, the role of cancer stem cells in resistance, and underlying mechanisms; it also presents future perspectives about strategies that could be used to target resistant cancer stem cells. Chapter 3 describes the factors associated with sensitivity and potential resistance of cancer cells to pseudomonas exotoxin-derived immunotoxins. Chapter 4 provides an overview of signaling pathways involved in resistance. Chapter 5 focuses on the treatment of hematologic neoplasms using antibody-drug conjugates, and immunotoxins. Chapter 6 discusses the challenges involved in pseudomonas exotoxin-based immunotoxins. Chapter 7 deals with resistance to the antibody-drug conjugate gentuzumab ozogamicin, while Chapter 8 discusses overcoming resistance to apoptosis using engineered human Granzyme B and Angiogenin. Chapter 9 presents immune responses in cancer and their therapeutic impact.

*Resistance to Immunotoxins in Cancer Therapy*, which includes reports about and reviews of cancer resistance, molecular and cellular mechanisms involved in resistance to targeted therapy, and methods to overcome resistance, is a comprehensive guide to the complete understanding of resistance to immunotoxins.

Rama Shanker Verma, Ph.D.

## About the Editor



**Rama Shanker Verma** is Professor, Indian Institute of Technology, Department of Biotechnology, Chennai, India. He is also Visiting Professor, Pondicherry University, Department of Biochemistry and Molecular Biology, and Visiting Professor, University of Madras. His awards and fellowships include a UNESCO fellowship and the Genomic Pioneer Recognition Award from HUGO. Professor Verma was recently elected Fellow, AMI, and is Fellow, Indian Academy of Science, India.

# Contents

<b>1 Targeted Cancer Therapy: History and Development of Immunotoxins</b> .....	1
Sudarshan Gadadhar and Anjali A. Karande	
1.1 Introduction .....	3
1.2 Chemotherapy .....	3
1.3 Cancer Immunotherapy .....	4
1.3.1 Antibodies in Cancer Therapy .....	4
1.3.2 Tumor Antigens .....	5
1.3.3 Antibodies for the Clinic .....	5
1.3.4 Antibodies as Carriers .....	6
1.4 Immunotoxins in Cancer Therapy .....	8
1.4.1 Targeting Moiety .....	9
1.4.2 Toxins in Cancer Immunotherapy .....	10
1.5 Construction of an Immunotoxin .....	17
1.6 Internalization and Cytotoxic Activity of Immunotoxins .....	17
1.7 Immunotoxins in Clinical Study .....	18
1.8 Conclusions .....	25
References .....	26
<b>2 Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective</b> .....	33
Sithambaram Devilakshmi, Jayaprakasam Madhumathi and Rama Shanker Verma	
2.1 Introduction .....	34
2.2 Factors Responsible for Cancer Resistance .....	35
2.2.1 Gene Mutations in Signalling Pathways .....	35
2.2.2 Drug Transporters .....	36
2.2.3 Tumor Microenvironment and Accessibility .....	36
2.3 Resistance to Immunotoxins .....	37
2.3.1 Dysfunctional Apoptotic Pathways .....	37
2.3.2 ABC Transporters .....	40



2.3.3	Lysosomal Degradation .....	40
2.3.4	Other Factors .....	41
2.4	Cancer Stem Cells and Resistance .....	41
2.4.1	Drug Efflux .....	41
2.4.2	Detoxification and Cellular Repair .....	42
2.4.3	DNA Repair and Modification .....	43
2.4.4	Survival Pathways .....	44
2.4.5	Autophagy and EMT .....	44
2.4.6	Quiescence .....	44
2.4.7	Microenvironment .....	44
2.5	Strategies Used to Overcome Resistance .....	45
2.5.1	Inhibitors of Anti-apoptotic Proteins .....	45
2.5.2	Blocking Membrane Drug Transporters .....	46
2.5.3	Delivery and Intracellular Trafficking .....	46
2.5.4	Inhibition of DNA Repair and Telomerase Activity .....	46
2.5.5	Combination Therapy .....	47
2.5.6	Nanotechnology .....	48
2.5.7	Other Novel Strategies .....	48
2.6	Targeting Cancer Stem Cells .....	49
2.6.1	Targeting Signaling Pathways in CSC's .....	49
2.6.2	Targeting Apoptosis and Cellular Repair Mechanisms in CSC's .....	50
2.6.3	Targeting Autophagy and Microenvironment in CSC's .....	51
2.6.4	Targeting Membrane Transporters and CSC Surface Markers .....	51
2.7	Conclusion .....	51
	References .....	52
<b>3</b>	<b>Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins .....</b>	<b>57</b>
	Sebastian Stahl, Fabian Mueller, Ira Pastan and Ulrich Brinkmann	
3.1	Introduction .....	58
3.2	Intoxication Pathways Define Determinants for Sensitivity and/or Resistances of Tumor Cells Towards Immunotoxins .....	60
3.3	Step 1—Access to Target Cells: Immunogenicity can be a Relevant Factor for Immunotoxin Therapy .....	62
3.4	Step 2—Target Cell Binding: Loss or Reduction of Target Antigens Reduce Sensitivity of Tumor Cells Towards Targeted Toxins .....	63
3.5	Step 3—Entry of Toxins into Cells: Loss of Processing Enzymes and Modulation of Vesicular Compartments Reduce Toxin Activity in Cultured Cells .....	64

3.6	Step 4—ADP-Ribosylation of eEF2: Reduced or Altered Expression of Diphthamide Synthesis Genes is Associated with Immunotoxin Resistances .....	65
3.7	Step 5—Signaling and Apoptosis: Protective Factors and Pathways can Reduce Toxin Sensitivity .....	66
3.8	Conclusions and Outlook .....	68
	References .....	69
<b>4</b>	<b>Cell Signaling and Resistance to Immunotoxins</b> .....	<b>75</b>
	Roland B. Walter	
4.1	Introduction .....	76
4.2	Conceptual Considerations on Cellular Immunotoxin Resistance .....	77
4.2.1	Alteration of Immunotoxin Resistance via Modulation of Caspase Activation Pathways .....	78
4.2.2	Resistance Mediated by the Cellular Apoptosis Susceptibility Gene .....	80
4.2.3	Resistance Mediated by Insulin-Like Growth Factor Signaling .....	80
4.2.4	Immunotoxin Resistance via Interference with Diphthamide Synthesis .....	80
4.2.5	Modulation of Immunotoxin Resistance via PI3K/AKT Signaling .....	81
4.2.6	Immunotoxin Resistance via Drug Transporter Activity .....	81
4.2.7	Modulation of Immunotoxin Resistance via Cytokine Signaling .....	82
4.2.8	Modulation of Immunotoxin Resistance via Protein Kinase C Signaling? .....	82
4.3	Conclusion .....	83
	References .....	83
<b>5</b>	<b>Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms</b> .....	<b>89</b>
	Tadeusz Robak and Pawel Robak	
5.1	Introduction .....	91
5.2	Anti-CD33 Immunotoxins for Acute Myeloid Leukemia .....	91
5.2.1	Gemtuzumab Ozogamicin .....	94
5.2.2	AVE9633 .....	97
5.2.3	HUM-195/rGEL .....	98
5.2.4	SGN-CD33A .....	98
5.3	Antibody-Drug Conjugates for B-Cell Lymphoid Malignancies .....	99
5.3.1	Anti-CD22 Immunotoxins .....	99
5.3.1.1	Inotuzumab Zogamycin .....	99
5.3.1.2	BL22 .....	102

5.3.1.3	Moxetumomab Pasudotox .....	103
5.3.1.4	Pinatuzumab Vedotin .....	103
5.3.2	Anti-CD25 Immunotoxins .....	104
5.3.3	Anti-CD19 Immunotoxins .....	104
5.3.3.1	SAR-3419 .....	104
5.3.3.2	Combotox .....	105
5.3.3.3	DT2219ARL .....	108
5.3.3.4	SGN-CD19A .....	108
5.3.4	Anti- CD70 Immunotoxins .....	109
5.3.4.1	MDX-1203 .....	109
5.3.4.2	SGN-75 .....	109
5.3.5	Anti-CD79: Polatuzumab Vedotin .....	110
5.3.6	Anti-CD30: Brentuximab Vedotin .....	110
5.3.7	Anti-CD37: IMGN529 .....	111
5.4	Immunotoxins for T-Cell Lymphoid Malignancies .....	112
5.4.1	Brentuximab Vedotin .....	112
5.4.2	Denileukin Diftitox .....	114
5.4.3	A-dmDT390-bisFv (UCHT1) .....	115
5.5	Hodgkin Lymphoma .....	116
5.6	Immunoconjugates for Multiple Myeloma .....	117
5.6.1	Milatumuzumab-Doxorubicin Antibody-Drug Conjugate .....	117
5.6.2	Indatuximab Ravtansine .....	118
5.6.3	Lorvotuzumab Mertansine .....	119
5.7	Conclusions .....	120
	References .....	121
<b>6</b>	<b>Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins</b> .....	<b>129</b>
	Vladimir Dergachev and Itai Benhar	
6.1	Introduction .....	130
6.2	Immunotoxins .....	131
6.3	Brief Historical Overview of PE-Based ITs .....	132
6.4	Immunogenicity of PE-based RITs and Solutions for Reducing it .....	137
6.5	Limited Stability of PE-Based RITs and How it Was Overcome by Antibody and Toxin Engineering .....	145
6.6	Insufficient Potency and Combining Therapies to Enhance Potency .....	148
6.7	Potential of RITs by Affinity Maturation of the Targeting Antibody .....	152
6.8	Reducing Off-Target Toxicity and Overcoming Physical Barriers .....	154
	References .....	157

<b>7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy</b> .....	165
Miwa Adachi and Akihiro Takeshita	
7.1 Introduction .....	166
7.2 CD33 .....	167
7.2.1 Gentuzumab Ozogamicin (GO) .....	168
7.2.2 GO Monotherapy, Phase I Study .....	169
7.2.3 Phase II Study .....	170
7.2.4 Drug Resistance via P-glycoprotein .....	170
7.2.5 GO Treatment with MDR Modifier, CyA .....	171
7.2.6 Drug Resistance Other Than P-glycoprotein .....	172
7.2.7 Phase III Study with GO for AML and Disappearance from the Market .....	173
7.2.8 Subsequent Phase III Study for AML .....	174
7.2.9 The Efficacy of GO for Acute Promyelocytic Leukemia (APL) .....	175
7.3 CD22 .....	176
7.3.1 Inotuzuma Bozogamicin .....	176
7.3.2 Drug Resistance of IO .....	176
7.4 Conclusion .....	177
References .....	177
<b>8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins</b> .....	185
Christian Cremer, Grit Hehmann-Titt, Sonja Schiffer, Georg Melmer, Paolo Carloni, Stefan Barth and Thomas Nachreiner	
8.1 Introduction: From Classical Immunotoxins to Human Cytolytic Fusion Proteins .....	187
8.2 Human Granzyme B .....	190
8.2.1 The Role of Granzyme B in Immune Surveillance .....	190
8.2.2 Therapeutic Potential and Limitations of Granzyme B for the Treatment of Cancer .....	193
8.2.3 Regulation of Granzyme B Activity by PI-9 .....	194
8.2.4 Therapeutic Options to Restore the Sensitivity of PI-9-Positive Tumors Against Granzyme B .....	196
8.2.4.1 Downregulation of PI-9 Expression and Activity .....	196
8.2.4.2 Design of Granzyme B Variants that are Insensitive Towards PI-9 .....	197
8.2.4.3 Therapeutic Efficacy of hCFPs Based on GrBR201K .....	198

- 8.3 Human Angiogenin ..... 199
  - 8.3.1 Targeted Cell Depletion Using Human Angiogenin ..... 201
  - 8.3.2 Generation of Angiogenin Mutants with Improved Cytotoxicity ..... 203
    - 8.3.2.1 Enhancing Cytosolic Translocation and Retention ..... 203
    - 8.3.2.2 Increasing the Enzymatic Activity of Angiogenin ..... 204
    - 8.3.2.3 Reducing the Susceptibility of Angiogenin to Inhibition ..... 204
    - 8.3.2.4 Angiogenin Variants with Several Modified Properties ..... 205
- 8.4 Conclusion ..... 206
- References ..... 206
  
- 9 Therapeutic Impact of Immune Responses in Cancer . . . . . 221**  
Michael Bette
  - 9.1 Introduction: Milestones in Cancer Research ..... 222
  - 9.2 Immunotherapies at the Beginning of the Twenty-First Century ..... 225
  - 9.3 Cell-Based Cancer Immunotherapies ..... 226
  - 9.4 Tumor Cells Transgenic for Cytokines Used in ACT ..... 228
  - 9.5 Antigen Presenting Cells Transgenic for Tumor Antigens Used in Adoptive Cell Transfer ..... 235
  - 9.6 T Cells Used in Adoptive Cell Transfer ..... 237
  - References ..... 239
  
- Index . . . . . 247**

# Contributors

**Miwa Adachi** Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

**Stefan Barth** Department of Pharmaceutical Product Development, Fraunhofer-Institute for Molecular Biology and Applied Ecology, Aachen, Germany

Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany

**Itai Benhar** Department of Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Israel

**Michael Bette** Department of Molecular Neuroscience, Institute of Anatomy and Cell Biology, Philipps University, Marburg, Germany

**Ulrich Brinkmann** Roche Pharma Research & Early Development pRED, Large Molecule Research, Roche Innovation Center Penzberg, Penzberg, Germany

**Paolo Carloni** Computational Biophysics, German Research School for Simulation Sciences, Jülich, Germany

**Christian Cremer** Department of Pharmaceutical Product Development, Fraunhofer-Institute for Molecular Biology and Applied Ecology, Aachen, Germany

**Vladimir Dergachev** Department of Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Israel

**Sithambaram Devilakshmi** Stem Cell and Molecular Biology Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India

**Sudarshan Gadadhar** Department of Biochemistry, Indian Institute of Science, Bangalore, Karnataka, India

**Grit Hehmann-Titt** Pharmedartis GmbH, Aachen, Germany

**Anjali A. Karande** Department of Biochemistry, Indian Institute of Science, Bangalore, Karnataka, India

**Jayaprakasam Madhumathi** Stem Cell and Molecular Biology laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India

**Georg Melmer** Pharmedartis GmbH, Aachen, Germany

**Fabian Mueller** Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

**Thomas Nachreiner** Department of Pharmaceutical Product Development, Fraunhofer-Institute for Molecular Biology and Applied Ecology, Aachen, Germany

**Ira Pastan** Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

**Pawel Robak** Experimental Hematology, Medical University of Lodz, Lodz, Poland

**Tadeusz Robak** Departments of Hematology, Medical University of Lodz, Lodz, Poland

**Sonja Schiffer** Department of Pharmaceutical Product Development, Fraunhofer-Institute for Molecular Biology and Applied Ecology, Aachen, Germany

**Sebastian Stahl** Roche Pharma Research & Early Development pRED, Large Molecule Research, Roche Innovation Center Penzberg, Penzberg, Germany

**Akihiro Takeshita** Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

**Rama Shanker Verma** Stem Cell and Molecular Biology laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India

**Roland B. Walter** Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Department of Medicine/Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA

Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA